BARDA Awards Up To $143 Million For Advanced Development Of A New Drug To Treat Anthrax
The HHS Biomedical Advanced Research and Development Authority (BARDA) awarded a contract to Elusys Therapeutics, Inc. of Pine Brook, N.J., for the advanced development of a medication to treat inhalational anthrax, one of the top bioterrorism threats facing the nation. The first year of the contract, called the base year, is valued at $16.8 million…
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
Comments are closed.